Bob was nominated by JDRF, not only for his tireless efforts and support of the Ride to Cure Diabetes and Spring Gala, but also for his 30+ years serving the Dane County community through his professional, civic, and charitable contributions. Congratulations Bob!

For more information see the article in the November 2011 Madison Magazine People of the Year

MADISON, Wis. — Dean Clinic officials said on Monday that a former employee might have exposed some patients to blood-borne diseases like hepatitis and HIV during the last five years.

Clinic officials released a news release on Monday saying that they’ve informed state and local health officials about the results of their internal review. They said that the employee conducted “inappropriate use of insulin demonstration pens and finger stick devices” during patient visits between 2006 and 2011. They’re now contacting 2,345 patients to check if they were exposed to hepatitis B, hepatitis C and HIV.

Please see the entire story Clinic: Patients might have been exposed to Hepatitis, HIV at channel3000 .com.

A special care team has been set up to handle questions the number is 1-855-288-3326.

This issue features in-depth articles on research to prevent and control diabetic retinopathy, research to develop a vaccine for type 1 diabetes, diabetes self-care tips from experts, and much more.

Check it out at http://countdown.jdrf.org/

WIAA Division 1 girls basketball: Middleton’s Gardner hasn’t let diabetes slow her down

Happy 2011!

We’re kicking off our first webcast of the new year with a live Q+A session with JDRF’s Chief Scientific Officer, Dr. Richard Insel.

This month, we’re going to focus on research in the prevention of type 1 diabetes. At its core, the goal of prevention science is to prevent type 1 diabetes from developing in people who are at risk for the disease. But prevention research may also have important benefits for people currently living with type 1 diabetes.

Some of the topics Dr. Insel will address include:

o What research is JDRF doing to understand the causes of type 1 diabetes? Is it in the genes? Is it caused by the environment?

o What is being done to prevent the disease from developing in those at risk?

o How will prevention research help people who already have type 1 diabetes?

o Are there any promising treatments out there now that can prevent or delay the onset of type 1 diabetes?

o What kinds of clinical trials are available today that families affected by type 1 diabetes can join to reduce the likelihood of more family members developing type 1 diabetes?

The incidence of type 1 diabetes has steadily increased over the past couple of decades. An estimated 3 million Americans currently have type 1 diabetes, and approximately 15,000 adults and 15,000 children are diagnosed with the disease every year.
Submit your questions via live chat at www.jdrf.org/livewebcasts this coming Tuesday, Jan. 25, at 2:00 PM EST. The program is scheduled to last 1 hour.

You may also ask your questions via email by sending them to webcast@jdrf.org.

The U.S. Food and Drug Administration today announced the agency is working with Abbott Diabetes Care to recall 359 different lots of glucose test strips marketed under the following brand names:

• Precision Xceed Pro;
• Precision Xtra;
• Medisense Optium;
• Optium;
• OptiumEZ; and
• ReliOn Ultima

These strips are used with Abbott’s Precision Xtra, Precision Xceed Pro, MediSense Optium, Optium, Optium EZ and ReliOn Ultima blood glucose monitoring systems. As many as 359 million strips may be affected by the recall. The blood glucose monitoring systems are not affected by this recall.

Read the full press release.

Read the full article at JDRF here

The program will focus on developing a better understanding of the autoimmune response that causes human type 1 diabetes and discovering novel therapeutic approaches to eliminate or prevent the autoimmune response.”

You can read more at JDRF.org.